The role of sirolimus in the treatment of vascular anomalies

Jakub Kopeć; Aleksandra Gawłowska; Ewa Kopeć; Przemysław Przewratil

doi:10.5114/fmpcr.2022.115879

eISSN: 2449-8580
ISSN: 1734-3402

Family Medicine & Primary Care Review

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Open access

2/2022
vol. 24

Send email

Copy url:

Review paper

The role of sirolimus in the treatment of vascular anomalies

Jakub Kopeć

¹

,

Aleksandra Gawłowska

¹

,

Ewa Kopeć

²

,

Przemysław Przewratil

¹

Department of Paediatric Surgery and Oncology, Paediatrics Centre of Lodz Medical University, Poland
Department of Family Medicine, Primary Health Care Clinic in Raciaz, Poland

Family Medicine & Primary Care Review 2022; 24(2): 168–171

DOI: https://doi.org/10.5114/fmpcr.2022.115879

Online publish date: 2022/06/30

Article file

- 13 FM&PCR 2 22 - R - Kopeć - The role - 1128.pdf [0.41 MB]

Get citation

PlumX metrics:

1. Sandbank S, Molho-Pessach V, Farkas A, et al. Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review. Acta Derm Venereol 2019; 99, doi: 10.2340/00015555-3262.

2. Wiegand S, Wichmann G, Dietz A. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review. Lymphat Res Biol 2018; 16(4): 330–339, doi: 10.1089/lrb.2017.0062.

3. Hori Y, Ozeki M, Hirose K, et al. Analysis of mTOR pathway expression in lymphatic malformation and related diseases. Pathol Int 2020; 70(6): 323–329, doi: 10.1111/pin.12913.

4. Wang Z, Zheng C, Sun H, et al. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma. Dermatology 2020; 236: 262–270, doi: 10.1159/000503604.

5. Pandeya V, Tiwarib P, Sharmaa P, et al. Development of a biomarker of efficacy in second-line treatment for lymphangioma of the tongue: a pilot study. Br J Oral Maxillofac Surg 2019; 57(10): 1137–1142, doi: 10.1016/j.bjoms.2019.10.303.

6. Zhang B, Li L, Zhang N, et al. 2019. Efficacy and safety of sirolimus in the treatment of blue rubber bleb naevus syndrome in paediatric patients. Clin Exp Dermatol 2019; 45(1): 79–85, doi: 10.1111/ced.14003.

7. Strychowsky JE, Rahbar R, O’Hare MJ, et al. Sirolimus as Treatment for 19 Patients with Refractory Cervicofacial Lymphatic Malformation. Laryngoscope 2017; 128(1): 269–276, doi: 10.1002/lary.26780.

8. Adams DM, Trenor CC, Hammill AM. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics 2016; 137(2): e20153257, doi: 10.1542/peds.2015-3257.

9. Triana P, Dore M, Cerezo VN, et al. Sirolimus in the Treatment of Vascular Anomalies. European J Pediatr Surg Rep 2016; 27(1): 86–90, doi: 10.1055/s-0036-1593383.

10. Dodds M, Tollefson M, Castelo-Soccio L, et al. Treatment of superficial vascular anomalies with topical sirolimus: a multicenter case series. Pediatr Dermatol 2020; 37(2): 272–277, doi: 10.1111/pde.14104.

11. Leducq S, Caille A, Barbarot S, et al. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. Trials 2019; 20: 739, doi: 10.1186/s13063-019-3767-8.

12. Marques L, Nunez-Cordoba JM, Aguado L, et al. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: Phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial. J Am Acad Dermatol 2014; 72(1): 151–158.E1, doi: 10.1016/j.jaad.2014.10.011.

13. Ozeki M, Asada R, Saito AM, et al. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: a study protocol for an open-label, single-arm, multicenter, prospective study (SILA). Regen Ther 2019: 84–91, doi: 10.1016/j.reth.2018.12.001.

14. Schreiber KH, Arriola Apelo SI, Yu D. A novel rapamycin analog is highly selective for mTORC1 in vivo. Nature Communications 2019; 10: 3194, doi: 10.1038/s41467-019-11174-0.

Copyright: © 2022 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

The role of sirolimus in the treatment of vascular anomalies

Jakub Kopeć 1 , Aleksandra Gawłowska 1 , Ewa Kopeć 2 , Przemysław Przewratil 1

Jakub Kopeć

¹

,

Aleksandra Gawłowska

¹

,

Ewa Kopeć

²

,

Przemysław Przewratil

¹